Thursday, August 7, 2008

Genomic Health, Inc. (GHDX) - a whopping 40% of its float short - New FusionIQ Short Squeeze

Genomic Health, Inc. (GHDX) a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer scored a base breakout and a new FusionIQ Short Squeeze.  With a whopping 40.00 + % of its float short and a point and figure target of $ 32.50 GHDX shares offer investors solid upside potential over the int. term.

Did you also know that Fusion offers money management services? Take our complimentary risk profile at or call us toll free at 1-888-661-2022 to set up a call with an advisor.



No comments:

Post a Comment